Trials / Withdrawn
WithdrawnNCT00517218
This Study is Being Performed to Evaluate the Effect of Genasense on the Efficacy and the Safety of Rituximab/Fludarabine Combination Treatment in Previously Untreated Subjects With Chronic Lymphocyctic Leukemia(CLL)
A Randomized Phase 3 Study of Fludarabine and Rituximab With or Without Genasense® (Oblimersen Sodium) in Previously Untreated Subjects With Chronic Lymphocytic Leukemia
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Genta Incorporated · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
To compare the efficacy and safety of combination treatment with Genasense, fludarabine, and rituximab versus combination treatment with fludarabine and rituximab in previously untreated subjects with CLL.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Genasense® (, oblimersen sodium G3139) |
Timeline
- Start date
- 2006-06-01
- Completion
- 2009-06-01
- First posted
- 2007-08-16
- Last updated
- 2008-02-11
Source: ClinicalTrials.gov record NCT00517218. Inclusion in this directory is not an endorsement.